Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 8, 2016, Pages 879-895

  Juif, Pierre Eric ^a   Kraehenbuehl, Stephan ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Autoimmune diseases; cardiodynamic effect; fingolimod; first dose; lymphocytes; ponesimod; S1P1 receptor modulators

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMISELIMOD; CERALIFIMOD; DILTIAZEM; FINGOLIMOD; GSK 2018682; KETOCONAZOLE; OZANIMOD; PONESIMOD; SIPONIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATOR; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ACCUMULATION INDEX; AIRWAY OBSTRUCTION; AREA UNDER THE CURVE; BASAL CELL CARCINOMA; BLOOD VESSEL PERMEABILITY; BRADYCARDIA; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; CLINICAL EFFECTIVENESS; CONCENTRATION AT STEADY-STATE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; ECG ABNORMALITY; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART BLOCK; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; LYMPHOID ORGAN; MACULAR EDEMA; MAXIMUM PLASMA CONCENTRATION; MIGRATION INHIBITION; MULTICENTER STUDY (TOPIC); NEUROMODULATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SINUS BRADYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TITRIMETRY; TREATMENT INTERRUPTION; ANALOGS AND DERIVATIVES; ANIMAL; AUTOIMMUNE DISEASES; DRUG DESIGN; DRUG EFFECTS; LYMPHOCYTE; METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTES; LYSOPHOSPHOLIPIDS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84979940376     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2016.1196188     Document Type: Review

References (117)

1. S.Spiegel, S.Milstien Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003 May;4(5):397–407.
2. S.Spiegel, S.Milstien. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Reviews Immunol. 2011 Jun;11(6):403–415.
3. J.Chun, T.Hla, K.R.Lynch, et al. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2010 Dec;62(4):579–587.
4. 1 receptor.
5. M.H.Gräler, G.Bernhardt, M.Lipp. EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics. 1998 Oct 15;53(2):164–169.
6. D.S.Im, C.E.Heise, N.Ancellin, et al. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem. 2000 May 12;275(19):14281–14286.
7. P.Keul, K.Sattler, B.Levkau. HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev. 2007 Dec;12(3–4):301–306.
8. P.A.Calabresi, E.W.Radue, D.Goodin, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545–556.
9. V.Brinkmann, M.D.Davis, C.E.Heise, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453–21457.
10. V.Brinkmann, A.Billich, T.Baumruker, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Reviews Drug Discovery. 2010;9(11):883–897.•• Detailed review of the preclinical and clinical studies with fingolimod.
11. A.Groves, Y.Kihara, J.Chun. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013 May 15;328(1–2):9–18.
12. O.Aktas, P.Küry, B.Kieseier, et al. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol. 2010 Jul;6(7):373–382.
13. 5 receptors in immunomodulation.
14. Y.Takuwa, Y.Okamoto, K.Yoshioka, et al. Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta. 2008 Sep;1781(9):483–488.
15. H.Kataoka, K.Sugahara, K.Shimano, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2005 Dec;2(6):439–448.
16. H.Kataoka, K.Shimano, Y.Maeda, et al. MT-1303, a novel sphingosine 1-phosphate (S1P) receptor modulator, ameliorates experimental autoimmune encephalomyelitis (EAE) in mice. ECTRIMS: Mult Scler. 2015 Oct 8;115138:Abstract EP1317.
17. L.Japtok, B.Kleuser. The role of sphingosine-1-phosphate receptor modulators in the prevention of transplant rejection and autoimmune diseases. Curr Opin Investig Drugs. 2009 Nov;10(11):1183–1194.
18. M.Salvadori, K.Budde, B.Charpentier, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2006 Dec;6(12):2912–2921.
19. J.A.Cohen, F.Barkhof, G.Comi, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;Feb4362(5):402–415.•• The largest, powered, prospective trial versus active comparator with fingolimod allowing its approval for the treatment of RRMS.
20. L.Kappos, J.Antel, G.Comi, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006 Sep 14;355(11):1124–1140.
21. L.Kappos, E.W.Radue, P.O’Connor, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387–401.
22. FDA approves first oral drug to reduce MS relapses. [cited 22 Sep 2010]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm
23. J.Chun, V.Brinkmann. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. 2011 Sep;12(64):213–228.
24. L.Piali, S.Froidevaux, P.Hess, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337(2):547–556.
25. T.Komiya, K.Sato, H.Shioya, et al. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. Clin Exp Immunol. 2013 Jan;171(1):54–62.
26. F.Scott, J.Brooks, B.Clemons, et al. Metabolites of RPC1063, a potent and selective S1P1R modulator, contribute to in vivo efficacy. Receptos, Inc 2013. http://files.shareholder.com/downloads/AMDA-1S4LZL/0x0x674893/48ECD974-C57D-4504-9260-E10C876DE945/AAN_2013_Poster_RPC1063_Metabolites.pdf
27. P.Gergely, B.Nuesslein-Hildesheim, D.Guerini, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035–1047.• Study to characterize the immunomodulatory potential and heart rate effect of siponimod using in vitro and in vivo approaches.
28. S.Mandala, R.Hajdu, J.Bergstrom, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002 Apr 12;296(5566):346–349.
29. 1 receptors in lymphocyte egress from thymus and secondary lymphoid organs.
30. M.G.Sanna, J.Liao, E.Jo, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839–13848.
31. S.R.Schwab, J.G.Cyster. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007 Dec;8(12):1295–1301.
32. S.R.Schwab, J.P.Pereira, M.Matloubian, et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005 Sep 9;309(5741):1735–1739.
33. K.Chiba, H.Matsuyuki, Y.Maeda, et al. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol. 2006 Feb;3(1):11–19.
34. J.G.Cyster. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. 2005;23:127–159.
35. C.Christoffersen, H.Obinata, S.B.Kumaraswamy, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9613–9618.
36. N.Murata, K.Sato, J.Kon, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000 Dec 15;352(Pt 3):809–815.
37. Y.Yatomi, Y.Igarashi, L.Yang, et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem. 1997 May;121(5):969–973.
38. R.Pappu, S.R.Schwab, I.Cornelissen, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007 Apr 13;316(5822):295–298.
39. Y.Yatomi, Y.Ozaki, T.Ohmori, et al. Sphingosine 1-phosphate: synthesis and release. Prostaglandins Other Lipid Mediat. 2001 Apr;64(1–4):107–122.
40. T.H.Pham, P.Baluk, Y.Xu, et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med. 2010 Jan 18;207(1):17–27.
41. C.G.Lo, Y.Xu, R.L.Proia, et al. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med. 2005 Jan 17;201(2):291–301.
42. C.H.Liu, S.Thangada, M.J.Lee, et al. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell. 1999 Apr;10(4):1179–1190.
43. H.Matsuyuki, Y.Maeda, K.Yano, et al. Involvement of sphingosine 1-phosphate (S1P) receptor type 1 and type 4 in migratory response of mouse T cells toward S1P. Cell Mol Immunol. 2006 Dec;3(6):429–437.
44. M.L.Oo, S.Thangada, M.T.Wu, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007 Mar 23;282(12):9082–9089.
45. P.Brossard, H.Derendorf, J.Xu, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013 Dec;76(6):888–896.
46. P.Brossard, M.Scherz, A.Halabi, et al. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: Favorable impact of dose up-titration. J Clin Pharmacol. 2014 Jan 9;54(2):179–188.
47. J.M.Kovarik, R.Schmouder, D.Barilla, et al. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004 May;44(5):532–537.
48. J.M.Kovarik, R.Schmouder, D.Barilla, et al. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004 May;57(5):586–591.
49. T.Olsson, A.Boster, O.Fernandez, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014 Apr 8;85(11):1198–1208.
50. K.Selmaj, D.K.Li, H.P.Hartung, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013 Aug;12(8):756–767.
51. A.Vaclavkova, S.Chimenti, P.Arenberger, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014 Aug 8;384(9959):2036–2045.
52. W.Sandborn, B.Feagan, D.Wolf, et al. A randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe ulcerative colitis: results of the TOUCHSTONE study. Congess of European Crohn’s and Colitis Organisation; 2015 Feb 18; Barcelona.
53. S.L.Hauser, E.Waubant, D.L.Arnold, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14;358(7):676–688.
54. D.D’Ambrosio, J.Steinmann, P.Brossard, et al. Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations. Immunopharmacol Immunotoxicol. 2015 Feb;37(1):103–109.
55. S.Krösser, P.Wolna, T.Z.Fischer, et al. Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm. J Clin Pharmacol. 2015 Apr 8;55(9):1051–1060.
56. M.Mehling, V.Brinkmann, J.Antel, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008 Oct 14;71(16):1261–1267.
57. M.Mehling, T.A.Johnson, J.Antel, et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology. 2011 Feb 22;76(8 Suppl 3):S20–7.
58. J.Rudnicka, M.Czerwiec, E.Grywalska, et al. Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study. Central-European Journal of Immunology /Polish Society for Immunology and Eleven Other Central-European Immunological Societies. 2015;40(3):354–359.
59. Z.Y.Song, R.Yamasaki, Y.Kawano, et al. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. Plos One. 2014;10(4):e0124923.
60. L.M.Vaessen, N.M.van Besouw, W.M.Mol, et al. FTY720 treatment of kidney transplant patients: a differential effect on B cells, naive T cells, memory T cells and NK cells. Transpl Immunol. 2006 Apr;15(4):281–288.
61. S.A.Jaigirdar, M.K.MacLeod. Development and function of protective and pathologic memory CD4 T cells. Front Immunol. 2015;6:456.
62. M.Kamanaka, S.Huber, L.A.Zenewicz, et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med. 2011 May 9;208(5):1027–1040.
63. J.Brooks, R.Peach, M.Boehm, et al. RPC1063, a potent, selective S1P1 receptor modulator, is active in a therapeutic EAE model and exhibits favourable PK/PD properties in healthy volunteers. ECTRIMS: Mult Scler. 2012;18:415. 33855.
64. D.Y.Vogel, E.J.Vereyken, J.E.Glim, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013;10:35.
65. J.R.Nofer, M.Bot, M.Brodde, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007 Jan 30;115(4):501–508.
66. B.D.Kahan, J.L.Karlix, R.M.Ferguson, et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplant. 2003 Oct 15;76(7):1079–1084.
67. Center, for, Drug, Evaluation, and, Research, et al. Application number: 22–527. Clinical pharmacology and biopharmaceutics review(s) [online] http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022527Orig1s000clinpharmr.pdf.
68. O.J.David, J.M.Kovarik, R.L.Schmouder. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012 Jan 1;51(1):15–28.
69. M.Zollinger, H.-P.Gschwind, Y.Jin, et al. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways. Drug Metab Dispos. 2011 Feb;39(2):199–207.
70. Novartis. Gilenya Prescribing Information. Aug 2015.
71. J.M.Kovarik, A.Slade, B.Voss, et al. Ethnic sensitivity study of fingolimod in white and Asian subjects. Int J Clin Pharmacol Ther. 2007 Feb;45(2):98–109.
72. J.M.Kovarik, M.Lu, G.-J.Riviere, et al. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. Eur J Clin Pharmacol. 2008 May;64(5):457–463.
73. N.Guerard, C.Zwingelstein, M.Hoch, et al. The effect of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of ponesimod, a Selective S1P receptor modulator. Basic Clin Pharmacol Toxicol. 2015 Nov 3. Epub ahead of print
74. P.-E.Juif, M.Hoch, D.D’Ambrosio, et al. Biocomparison of three formulations of the S1P1 receptor modulator ponesimod in healthy subjects. Drugs R D. 2015 Jun;15(2):203–210.
75. 1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects. Eur J Pharm Sci. 2014 Jul 19;63:147–153.
76. M.W.Scherz, P.Brossard, D.D’Ambrosio, et al. Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects. J Clin Pharmacol. 2015 Jun;55(6):688–697.
77. M.Reyes, M.Hoch, P.Brossard, et al. Mass balance, pharmacokinetics and metabolism of the selective S1P receptor modulator ponesimod in humans. Xenobiotica. 2014 Sep;4:1–11.
78. M.Boehler, P.E.Juif, M.Hoch, et al. Absolute bioavailability of ponesimod, a selective S1P1 receptor modulator, in healthy male subjects. Eur J Drug Metab Pharmacokinet. In press.
79. M.Reyes, M.Hoch, P.Brossard, et al. Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects. Pharmacology. 2014;94(5–6):223–229.
80. G.Timony, J.Brooks, J.Hartung, et al. Pharmacokinetics and pharmacodynamics of RPC1063 and its metabolites in healthy adult volunteers (P1. 211). Neurology. 2014;82(10Supplement):P1.211–P1. 11.
81. K.Shakeri-Nejad, V.Aslanis, U.K.Veldandi, et al. Pharmacokinetics, safety and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment compared to demographically matched healthy subjects (P1. 135). Neurology. 2015;84(14Supplement):P1.135.
82. J.Xu, F.Gray, A.Henderson, et al. Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine‐1‐phosphate receptor modulator, in healthy volunteers. Clin Pharmacol Drug Dev. 2014;3(3):170–178.
83. A.Krause, P.Brossard, D.D’Ambrosio, et al. Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator. J Pharmacokinet Pharmacodyn. 2014 Jun;41(3):261–278.
84. C.Sarr, M.Savelieva, G.Ette, et al. Modeling dose-PK-lymphocytes relationship under siponimod (BAF312) treatment to infer time to immune reconstitution. Mult Scler J. 2014;2014:89.
85. G.Francis, L.Kappos, P.O’Connor, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Sclerosis. 2014 Apr;20(4):471–480.
86. H.Hartung, E.Pigeolet, D.Li, et al. The selective sphingosine 1-phosphate receptor modulator siponimod (BAF312): magnetic resonance imaging lesion and lymphocyte relationship in a phase 2 study in relapsing remitting multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2012 Oct 10–13; Lyon, France.
87. A.Olson, J.Hartung, G.Timony, et al. Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor modulator, in healthy adult volunteers, results of a phase 1 study. Neurology. 2013;80:P01.178.
88. FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs. [cited 2015 Aug8]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm456919.htm.
89. Receptos Prospectus. [cited 2013 May8]. Available from: http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=8871010.
90. European Medicines Agency. Gilenya 0.5mg hard capsules - Summary of Product Characteristics. Mar 2016.
91. U.S. Food and Drug Administration. GILENYA (fingolimod) capsules, for oral use HIGHLIGHTS OF PRESCRIBING INFORMATION. Feb 2016.
92. F.Lublin, D.H.Miller, M.S.Freedman, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075–1084.
93. K.Selmaj, D.Arnold, G.Comi, et al. Safety and tolerability results of the phase 2 portion of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis (P7. 199). Neurology. 2015;84(14Supplement):P7.199.
94. J.Liu, C.Zhang, W.Tao, et al. Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. Int J Neurosci. 2013 Mar;123(3):163–169.
95. Y.Hasegawa, H.Suzuki, T.Sozen, et al. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke. 2010 Feb;41(2):368–374.
96. P.Kraft, E.Gob, M.K.Schuhmann, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke. 2013 Nov;44(11):3202–3210.
97. Z.Zhu, Y.Fu, D.Tian, et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015 Sep 22;132(12):1104–1112.
98. J.S.Karliner. Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta. 2013 Jan;1831(1):203–212.
99. Keul P, Tolle M, Lucke S, von Wnuck Lipinski K, Heusch G, Schuchardt M, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):607–613.
100. G.Wang, R.Y.Kim, I.Imhof, et al. The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction. J Cardiovasc Pharmacol. 2014 Feb;63(2):132–143.
101. K.Sattler, M.Graler, P.Keul, et al. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol. 2015 Sep 29;66(13):1470–1485.
102. S.You, L.Piali, C.Kuhn, et al. Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes. Plos One. 2013;8(10):e77296.
103. V.Ratanatharathorn, L.Ayash, H.M.Lazarus, et al. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 2001 Jul;28(2):121–129.
104. L.Koyrakh, M.I.Roman, V.Brinkmann, et al. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2005 Mar;5(3):529–536.
105. M.G.Sanna, K.P.Vincent, E.Repetto, et al. Bitopic sphingosine 1-phosphate receptor 3 (S1P3) antagonist rescue from complete heart block: pharmacological and genetic evidence for direct S1P3 regulation of mouse cardiac conduction. Mol Pharmacol. 2016 Jan;89(1):176–186.
106. R.Schmouder, S.Hariry, O.J.David. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol. 2012 Apr;68(4):355–362.
107. E.Legangneux, A.Gardin, D.Johns. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol. 2013 Mar;75(3):831–841.
108. M.Forrest, S.Y.Sun, R.Hajdu, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004 May;309(2):758–768.
109. J.DiMarco, P.O’Connor, J.Cohen, et al. First-dose effect of fingolimod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS)(P830). Mult Sclerosis. 2010;16(Suppl 10):S290.
110. M.Hoch, A.Vaclavkova, A.Krause, et al. A novel gradual up-titration regimen mitigates the first-dose effects of ponesimod, a selective S1P1 receptor modulator. Clin Ther. 2015;37(8):e36–e37.
111. S.Biswal, F.Polus, P.Pal, et al. Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects. Int J Clin Pharmacol Ther. 2015 Oct;53(10):855–865.
112. R.Schmouder, D.Serra, Y.Wang, et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006 Aug;46(8):895–904.
113. M.Hoch, B.Darpo, P.Brossard, et al. Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals. Basic Clin Pharmacol Toxicol. 2015 May;116(5):429–437.
114. K.Shakeri-Nejad, V.Aslanis, U.K.Veldandi, et al. Effects of therapeutic and supratherapeutic doses of siponimod (BAF312) on cardiac repolarization in healthy subjects. Clin Ther. 2015 Nov 1;37(11):2489–505e2.
115. S.Simula, T.Laitinen, T.M.Laitinen, et al. Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis. Mult scler 2015 Sep 11 Epub ahead of print.
116. V.Racca, M.Di Rienzo, R.Cavarretta, et al. Fingolimod effects on left ventricular function in multiple sclerosis. Mult Sclerosis. 2016 Feb;22(2):201–211.
117. New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&mid=WC0b01ac058004d5c1: European Medicines Agency.